BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28905400)

  • 1. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
    Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
    Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
    Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
    Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
    FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
    Jia L; Gui B; Zheng D; Decker KF; Tinay I; Tan M; Wang X; Kibel AS
    Prostate; 2017 Jun; 77(9):1000-1011. PubMed ID: 28422308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
    Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
    PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
    Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W
    Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.
    Ruscica M; Magni P; Steffani L; Gatto F; Albertelli M; Rametta R; Valenti L; Ameri P; Magnaghi V; Culler MD; Minuto F; Ferone D; Arvigo M
    Mol Cell Endocrinol; 2014 Feb; 382(2):860-70. PubMed ID: 24211300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
    Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
    Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA cir-ITCH Is a Potential Therapeutic Target for the Treatment of Castration-Resistant Prostate Cancer.
    Li S; Yu C; Zhang Y; Liu J; Jia Y; Sun F; Zhang P; Li J; Guo L; Xiao H; Gao F; Deng X; Cai Z; Cai J
    Biomed Res Int; 2020; 2020():7586521. PubMed ID: 32904490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells.
    Modarai SR; Opdenaker LM; Viswanathan V; Fields JZ; Boman BM
    BMC Cancer; 2016 Dec; 16(1):941. PubMed ID: 27927191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of prostate cancer cell proliferation by somatostatin receptor activation.
    Ruscica M; Arvigo M; Gatto F; Dozio E; Feltrin D; Culler MD; Minuto F; Motta M; Ferone D; Magni P
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):254-62. PubMed ID: 19932151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
    Djusberg E; Jernberg E; Thysell E; Golovleva I; Lundberg P; Crnalic S; Widmark A; Bergh A; Brattsand M; Wikström P
    Prostate; 2017 May; 77(6):625-638. PubMed ID: 28144969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin and its receptor family.
    Patel YC
    Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.